# Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide

> **NCT05023941** · PHASE4 · COMPLETED · sponsor: **Ji Xunming,MD,PhD** · enrollment: 252 (actual)

## Conditions studied

- Acute Mountain Sickness

## Interventions

- **DRUG:** Acetazolamide
- **DEVICE:** Doctormate® (twice daily for 6 days)
- **DEVICE:** Doctormate® (forth daily for 3 days)

## Key facts

- **NCT ID:** NCT05023941
- **Lead sponsor:** Ji Xunming,MD,PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-30
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023941, "Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05023941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*